Dr. Steven Behram, MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 88
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
MD license DD55699
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Medical groups
- Privia Medical Group, LLC (1,533 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 88
- Services billed
- 379
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Urinalysis, manual test | 71 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 47 |
| Established patient office or other outpatient visit, 20-29 minutes | 51 | 33 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | 23 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 17 payments worth $350 in total to this clinician.
| Astellas Pharma US Inc | $165 |
|---|---|
| Lilly USA, LLC | $86.21 |
| Hologic Sales and Service, LLC | $38.80 |
| Novo Nordisk Inc | $24.96 |
| Coopersurgical, Inc. | $21.90 |
| Meditrina | $13.34 |
| Food and Beverage | $350 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $24,958 in research payments for these studies, mostly to the institutions running them.
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc. · Active, not recruiting · NCT04333576 - Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Mylan Inc. · Completed · NCT05139121 - M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Sev…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.